Giersing Birgitte, Mo Annie X, Hwang Angela, Baqar Shahida, Earle Kristen, Ford Andrew, Deal Carolyn, Dull Peter, Friede Martin, Hall B Fenton
Department of Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland.
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, MSC 9825, Bethesda, MD 20892-9825, USA.
Vaccine. 2025 Feb 6;46:126686. doi: 10.1016/j.vaccine.2024.126686. Epub 2025 Jan 5.
At the 2023 Global Vaccine and Immunization Research Forum (GVIRF), researchers from around the world gathered in the Republic of Korea to discuss advances and opportunities in vaccines and immunization. Many stakeholders are applying the lessons of Covid-19 to future emergencies, by advancing early-stage development of prototype vaccines to accelerate response to the next emerging infectious disease, and by building regional vaccine research, development, and manufacturing capacity to speed equitable access to vaccines in the next emergency. Recent vaccine licensures include: respiratory syncytial virus vaccines, both for the elderly and to protect infants through maternal immunization; a new dengue virus vaccine; and licensure of Covid-19 vaccines previously marketed under emergency use authorizations. Malaria vaccine implementation is expanding and a second malaria vaccine has been recommended by the World Health Organization. In a setback for human immunodeficiency virus vaccine development, the only remaining Phase 3 trial has been discontinued. In immunization, greater clarity is emerging on the challenges of achieving access and equity, along with strategies to address those challenges. A better understanding of behavioral and social determinants of vaccine uptake and a validated toolkit for measuring and modifying the drivers of vaccination is informing program design and service delivery, contributing to improved uptake. Implementation research, which has been essential for human papillomavirus and malaria vaccine delivery, will be critical for delivering the new respiratory syncytial virus vaccines and for many other vaccines currently in development. The growing diversity of vaccines and complexity of immunization programs are leading to greater interest in simplified regimens, combination vaccines, and other innovations to facilitate delivery. Collaboration emerged as the unifying theme of GVIRF 2023, underscoring that the combined efforts of many contributors have enabled progress thus far, and going forward will continue to be essential to ensure equitable access to vaccines for all.
在2023年全球疫苗与免疫研究论坛（GVIRF）上，来自世界各地的研究人员齐聚大韩民国，讨论疫苗与免疫领域的进展和机遇。许多利益相关者正在将新冠疫情的经验教训应用于应对未来的紧急情况，推进原型疫苗的早期开发以加速对下一次新发传染病的应对，并建设区域疫苗研究、开发和生产能力，以便在下次紧急情况中加快公平获取疫苗的速度。近期获批的疫苗包括：针对老年人的呼吸道合胞病毒疫苗以及通过母体免疫保护婴儿的呼吸道合胞病毒疫苗；一种新型登革病毒疫苗；以及此前根据紧急使用授权上市的新冠疫苗的获批。疟疾疫苗的推广正在扩大，世界卫生组织已推荐了第二种疟疾疫苗。在人类免疫缺陷病毒疫苗研发方面遭遇挫折，仅存的一项3期试验已停止。在免疫接种方面，实现疫苗可及性和平等性所面临的挑战以及应对这些挑战的策略正日益明晰。对疫苗接种行为和社会决定因素的更好理解以及用于衡量和改变疫苗接种驱动因素的经过验证的工具包，为项目设计和服务提供提供了依据，有助于提高疫苗接种率。实施研究对于人乳头瘤病毒和疟疾疫苗的推广至关重要，对于新的呼吸道合胞病毒疫苗以及目前正在研发的许多其他疫苗的推广也将至关重要。疫苗种类日益多样以及免疫规划日益复杂，使得人们对简化接种方案、联合疫苗及其他便于接种的创新措施的兴趣日益浓厚。合作成为2023年全球疫苗与免疫研究论坛的统一主题，凸显出众多贡献者的共同努力迄今已推动了进展，并且未来对于确保所有人公平获取疫苗仍将至关重要。
